Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers

Oncology Reports

Volumn 26, Issue 3, 2011, Pages 629-635

  Gründker, Carsten ^a   Ernst, Jennifer ^a   Reutter, Maditad ^a   Ghadimi, B Michael ^a   Emons, Günter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

AEZS 108; Luteinizing hormone releasing hormone receptor; Pancreatic cancer; Targeted therapy

Indexed keywords

AEZS 108; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL LOSS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DOXORUBICIN; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RECEPTORS, LHRH; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 79959946400     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1340     Document Type: Article

References (25)

1. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422, 2009.
2. Baumgart M, Heinmoller E, Horstmann O, Becker H and Ghadimi BM: The genetic basis of sporadic pancreatic cancer. Cell Oncol 27 3-13, 2005. (Pubitemid 40387188)
3. Tanase CP, Neagu M, Albulescu R and Hinescu ME: Advances in pancreatic cancer detection. Adv Clin Chem 51: 145-180, 2010.
4. Kornmann M, Beger HG and Link KH: Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res 161: 180-195, 2003.
5. Zalatnai A and Molnar J: Review. Molecular background of chemoresistance in pancreatic cancer. In Vivo 21: 339-347, 2007. (Pubitemid 46534289)
6. Friess H, Buchler M, Kiesel L, Kruger M and Beger HG: LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. Int J Pancreatol 10: 151-159, 1991.
7. Schally AV and Nagy A: Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15: 300-310, 2004. (Pubitemid 39193184)
8. Schally AV, Engel JB, Emons G, Block NL and Pinski J: Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 8: 11-25, 2011.
9. Gründker C, Günthert AR, Westphalen S and Emons G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 146: 1-14, 2002. (Pubitemid 34126412)
10. Schally AV and Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141: 1-14, 1999. (Pubitemid 29370830)
11. Günthert AR, Gründker C, Bongertz T, Nagy A, Schally AV and Emons G: Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Res Treat 87: 255-264, 2004. (Pubitemid 39505942)
12. Günthert AR, Gründker C, Bongertz T, et al: Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 191: 1164-1172, 2004. (Pubitemid 39421567)
13. Westphalen S, Kotulla G, Kaiser F, et al: Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17: 1063-1069, 2000.
14. Emons G, Ortmann O, Becker M, et al: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993. (Pubitemid 23342164)
15. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458-1464, 1993. (Pubitemid 24000896)
16. Irmer G, Bürger C, Müller R, et al: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822, 1995.
17. Gründker C, Schlotawa L, Viereck V, et al: Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151: 141-149, 2004. (Pubitemid 39117377)
18. Gründker C: Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological cancer therapy. Eur J Endocrinol 143: 569-572, 2000.
19. Gründker C, Völker P, Griesinger F, et al: Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 187: 528-537, 2002.
20. Wang Z, Li Y, Ahmad A, et al: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2010.
21. Lillemoe KD: Current management of pancreatic carcinoma. Ann Surg 221: 133-148, 1995.
22. Yeo CJ: Pancreatic cancer: 1998 update. J Am Coll Surg 187: 429-442, 1998.
23. Nitecki SS, Sarr MG, Colby TV and van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221: 59-66, 1995.
24. Conlon KC, Klimstra DS and Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223: 273-279, 1996.
25. Emons G, Tomov S, Harter P, et al: Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J Clin Oncol 28 (Suppl 15): 5035, 2010.